The first 60 days: Chronic lymphocytic leukaemia, first treatment
Chronic lymphocytic leukaemia is treated only when it causes problems, and chemotherapy has gone. The first treatment is now either a BTK inhibitor taken indefinitely or a one-year course of venetoclax with obinutuzumab (CLL14), and the two can be combined for a fixed course. Below, week by week, is what OnCo's record of Chronic lymphocytic leukaemia, first treatment says about the first two months: the order is typical, the timing is yours to ask about. Sections appear only where the record has something to say. Orientation, not medical advice.
What happens now
Staging tests establish exactly what and where the cancer is. Everything else follows from the answers.
Ask which of these were tested and what the results were; see the report reader for what each value means.
These specialties appear in the standard of care for this cancer. In most centres they meet weekly as a tumour board to agree each plan; you can ask when yours was discussed and what was decided.
- PathologistNamed in the standard of care for: Asymptomatic early-stage disease.
- Medical oncologistNamed in the standard of care for: First treatment, fixed duration, First treatment, continuous, Chemoimmunotherapy.
- Transplant and cell therapy teamNamed in the standard of care for: Chemoimmunotherapy.
A second opinion from a centre that treats many similar cases is normal, not rude; the standard of care tells you what to compare it against.
Each row is a setting from the standard of care, in the order it usually arises. Not all will apply to you; your stage and biomarkers decide which do. The guideline grade, where recorded, says how strong the evidence is.
- 1.Asymptomatic early-stage diseaseNCCN Guidelines: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Watch and wait with counts every three to twelve months; treat only on iwCLL indications.
- 2.First treatment, fixed durationNCCN Guidelines: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Venetoclax plus obinutuzumab for 12 months (CLL14, CLL13); ibrutinib-venetoclax (GLOW, CAPTIVATE) or acalabrutinib-venetoclax with or without obinutuzumab (AMPLIFY) for fit patients.
- 3.First treatment, continuousNCCN Guidelines: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Acalabrutinib (ELEVATE-TN) or zanubrutinib (SEQUOIA) until progression, preferred for del(17p) or TP53-mutated disease; ibrutinib where the newer agents are unavailable.
Fludarabine-cyclophosphamide-rituximab or bendamustine-rituximab only for IGHV-mutated disease without TP53 aberration where targeted drugs are unavailable; never for del(17p).
Generated from this cancer's standard of care, biomarkers and open problems. Take the group that matches where you are. To tick, add your own and print, open the one-page appointment sheet.
Newly diagnosed
- What is my exact diagnosis, stage, and grade, and which tests established them?Everything else follows from an accurate stage and subtype.
- Which biomarkers have been tested on my tumour (for example delby FISH and TP53 mutation, IGHV mutational status, CLL-IPI score, Beta-2 microglobulin, Complex karyotype), and what were the results?These results decide eligibility for targeted therapy, immunotherapy, and trials.
- Which subtype is my cancer, and does that change the recommended treatment?Recognised subtypes for this cancer include Treatment-naive CLL without delor TP53 mutation, IGHV mutated, Treatment-naive CLL, IGHV unmutated, Treatment-naive CLL with delor TP53 mutation.
- Is germline (inherited) genetic testing recommended for me or my family?Inherited variants can change treatment and matter for relatives.
Asymptomatic early-stage disease
- For my situation (asymptomatic early-stage disease), which of the standard options do you recommend and why?Guideline options include: Watch and wait with counts every three to twelve months; treat only on iwCLL indications.
First treatment, fixed duration
- For my situation (first treatment, fixed duration), which of the standard options do you recommend and why?Guideline options include: Venetoclax plus obinutuzumab for 12 months (CLL14, CLL13); ibrutinib-venetoclax (GLOW, CAPTIVATE) or acalabrutinib-venetoclax with or without obinutuzumab (AMPLIFY) for fit patients.
- Am I a candidate for Venetoclax, Obinutuzumab, Ibrutinib or related drugs, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of CLL14 and CLL13 / GAIA apply to someone like me?Trial populations differ from individual patients; ask how closely you match.
First treatment, continuous
- For my situation (first treatment, continuous), which of the standard options do you recommend and why?Guideline options include: Acalabrutinib (ELEVATE-TN) or zanubrutinib (SEQUOIA) until progression, preferred for del(17p) or TP53-mutated disease; ibrutinib where the newer agents are unavailable.
- Am I a candidate for Acalabrutinib, Zanubrutinib, Ibrutinib, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of ELEVATE-TN and SEQUOIA apply to someone like me?Trial populations differ from individual patients; ask how closely you match.
Chemoimmunotherapy
- For my situation (chemoimmunotherapy), which of the standard options do you recommend and why?Guideline options include: Fludarabine-cyclophosphamide-rituximab or bendamustine-rituximab only for IGHV-mutated disease without TP53 aberration where targeted drugs are unavailable; never for del(17p).
- Am I a candidate for Fludarabine, Cyclophosphamide, Rituximab or related drugs, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
Any stage
- Are there clinical trials I could join, for example of Sonrotoclax, Nemtabrutinib, CELESTIAL-TNCLL, CaDAnCe-304?Trials are how the next standard of care is set; asking early keeps options open.
- Would a second opinion at a high-volume centre change anything, and can you help arrange it?Rare or high-stakes decisions benefit from a centre that treats many similar patients.
- What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?Supportive care improves quality of life and helps patients complete treatment.
- I read that “Continuous BTK inhibitor or fixed-duration venetoclax first: no head-to-head survival data”. How does that affect my plan?Open problems are where trials and second opinions matter most.
- I read that “Whether MRD should decide how long fixed-duration therapy lasts”. How does that affect my plan?Open problems are where trials and second opinions matter most.
Trials open now for this cancer in OnCo, largest phase first. Joining a trial is a decision like any other: ask what the comparison arm is, whether a placebo is used, and what happens if you leave. The cancer page searches ClinicalTrials.gov live for more.
- BELLWAVE-011Phase 3 · recruiting · NCT06136559Previously untreated CLL/SLL: nemtabrutinib vs investigator's choice of ibrutinib or acalabrutinib
- CaDAnCe-304Phase 3 · recruitingRelapsed/refractory CLL/SLL after a covalent BTK inhibitor: BTK degrader BGB-16673 vs pirtobrutinib
- CELESTIAL-TNCLLPhase 3 · active · NCT06073821Previously untreated CLL/SLL: fixed-duration sonrotoclax + zanubrutinib vs venetoclax + obinutuzumab
Much of what helps in the first weeks is free if you know to ask: testing, helplines, rides and lodging, second opinions, trial travel.
- Chronic lymphocytic leukaemia, first treatment: the full pageChronic lymphocytic leukaemia is treated only when it causes problems, and chemotherapy has gone. The first treatment is now either a BTK inhibitor taken indefinitely or a one-year course of venetoclax with obinutuzumab (CLL14), and the two can be combined for a fixed course.
- One-page appointment sheetYour questions, the words you may hear, what to bring, and space for the answers. Print it.
- Treatment sequencingWhich treatment tends to follow which, line by line.
- NavigatorStandard of care for your stage, what you have tried, and trials near you.
- IGHV mutational status: Whether the leukaemia's antibody gene has been 'edited' by the immune system.
- del(17p) / TP53 aberration in CLL: A del(17p) deletion or TP53 mutation means loss or damage of the p53 safety gene in CLL.
- Undetectable MRD (uMRD / MRD-negative): The test for leftover cancer cells found none, down to the sensitivity of the assay (often one cell in 100,000 or a million).
- Flow cytometry (immunophenotyping): A machine that streams cells one by one past lasers and reads the surface proteins (CD markers) each carries, identifying what kind of cell it is.
- Tumour lysis syndrome (TLS): When a treatment kills cancer cells faster than the body can clear their contents, flooding the blood with potassium, phosphate and uric acid and injuring the kidneys and heart.
- TP53-mutated (p53-abnormal): Loss of the p53 'guardian of the genome', the most commonly mutated gene in cancer.
Every term links to the glossary.